Global, Regional, and National Burdens and Trends of Tracheal, Bronchial, and Lung Cancer in Individuals Aged 70 Years and Older from 1990 to 2021 (GDBlung70)

November 11, 2024 updated by: Hongquan Xing
Despite the increasing health burden of tracheal, bronchial, and lung (TBL) cancer patients aged ≥ 70 years worldwide, data on its burden and trends are limited. This study aimed to analyze the global, regional, and national burdens and trends of TBL cancer from 1990 to 2021.

Study Overview

Status

Completed

Conditions

Detailed Description

The latest cancer report indicates that tracheal, bronchial, and lung (TBL) cancer, the most widespread cancer globally, accounts for 12.4% of new diagnoses and 18.7% of cancer-related deaths, thereby presenting significant societal, public health, and economic challenges.Despite the increasing health burden of tracheal, bronchial, and lung (TBL) cancer patients aged ≥ 70 years worldwide, data on its burden and trends are limited. This study aimed to analyze the global, regional, and national burdens and trends of TBL cancer from 1990 to 2021.

Study Type

Observational

Enrollment (Actual)

111627

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

patients with lung cancer and aged 70 years and older

Description

Inclusion Criteria:

Pathologic Diagnosis of lung cancer

Exclusion Criteria:

breast cancer Age less than 70 years

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
NA

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The incidence, mortality, and disability-adjusted life years (DALYs) data for TBL cancer patients aged ≥ 70 years, spanning 1990-2021.
Time Frame: 1990-2021

We extracted the incidence, mortality, and disability-adjusted life years (DALYs) for TBL cancer in individuals aged ≥ 70 years and above along with their 95% uncertainty intervals (UIs) from the GBD 2021 database (https://vizhub.healthdata.org

/gbd-results/). The data were stratified by age groups and social determinants of the health index (SDI) regions, encompassing 21 global GBD regions and 204 countries.
1990-2021

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hongquan Xing

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 1990

Primary Completion (Actual)

October 10, 2024

Study Completion (Actual)

October 10, 2024

Study Registration Dates

First Submitted

November 11, 2024

First Submitted That Met QC Criteria

November 11, 2024

First Posted (Estimated)

November 19, 2024

Study Record Updates

Last Update Posted (Estimated)

November 19, 2024

Last Update Submitted That Met QC Criteria

November 11, 2024

Last Verified

January 1, 1990

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NanchangUN

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe